Clinical Trial Results:
A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma
Summary
|
|
EudraCT number |
2009-017237-22 |
Trial protocol |
BE DE ES CZ PT NL GB IT |
Global completion date |
08 Sep 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Mar 2020
|
First version publication date |
25 Mar 2020
|
Other versions |
|
Summary report(s) |
CNTO328MMY3001_Results Status |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.